We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00468988
First Posted: May 3, 2007
Last Update Posted: May 25, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Alcon Research
May 2, 2007
May 3, 2007
May 25, 2012
May 2007
July 2007   (Final data collection date for primary outcome measure)
Tear Break Up Time [ Time Frame: Day ]
Same as current
Complete list of historical versions of study NCT00468988 on ClinicalTrials.gov Archive Site
Safety [ Time Frame: Onset ]
Same as current
Not Provided
Not Provided
 
Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers
Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers
Compare the effect of Xalatan with benzalkonium chloride on the ocular surface to those effects observed with Travatan Z without benzalkonium chloride after a single dose
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Glaucoma
  • Drug: Travatan® Z
  • Drug: Xalatan®
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
July 2007
July 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults with primary open-angle glaucoma, ocular hypertension or pigment dispersion glaucoma

Exclusion Criteria:

  • Age
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00468988
SMA-06-21
Not Provided
Not Provided
Not Provided
Alcon Research
Alcon Research
Not Provided
Study Director: Mark Jasek, PhD Alcon Research
Alcon Research
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top